Menu
Search
|

Menu

Close
X

Biospecifics Technologies Corp BSTC.OQ (NASDAQ Stock Exchange Global Market)

58.42 USD
-- (--)
As of Sep 18
Previous Close 58.42
Open --
Volume --
3m Avg Volume 17,717
Today’s High --
Today’s Low --
52 Week High 73.31
52 Week Low 52.59
Shares Outstanding (mil) 7.29
Market Capitalization (mil) 430.73
Forward P/E 21.22
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 1 analysts

KEY STATS

Revenue (mm, USD)
FY19
8
FY18
32
FY17
27
FY16
26
EPS (USD)
FY19
0.602
FY18
2.659
FY17
1.698
FY16
1.563
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
21.22
33.85
Price to Sales (TTM)
vs sector
12.67
7.90
Price to Book (MRQ)
vs sector
4.21
4.38
Price to Cash Flow (TTM)
vs sector
19.25
23.70
Total Debt to Equity (MRQ)
vs sector
0.00
17.64
LT Debt to Equity (MRQ)
vs sector
0.00
12.61
Return on Investment (TTM)
vs sector
22.26
12.69
Return on Equity (TTM)
vs sector
22.27
17.13

EXECUTIVE LEADERSHIP

Ronald Law
Principal Executive Officer, Since 2019
Salary: $375,000.00
Bonus: --
Patrick Caldwell
Principal Financial Officer, Principal Accounting Officer, Since 2019
Salary: --
Bonus: --
Mark Wegman
Director, Since 2007
Salary: --
Bonus: --
Toby Wegman
Director, Since 2007
Salary: --
Bonus: --
Jennifer Chao
Independent Director, Since 2015
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

35 WILBUR ST
LYNBROOK   NY   11563-2358

Phone: +1516.5937000

BioSpecifics Technologies Corp. is a biopharmaceutical company involved in the development of an injectable collagenase clostridium histolyticum for multiple indications. The Company has a development and license agreement with Endo Global Ventures, a Bermuda unlimited liability company (Endo Global Ventures), an affiliate of Endo International plc (Endo), for injectable collagenase for marketed indications and indications in development. Injectable collagenase clostridium histolyticum is marketed as XIAFLEX (or Xiapex in Europe). The two marketed indications involving its injectable collagenase are Dupuytren's contracture and Peyronie's disease. The other clinical indications for which its collagenase injection has been tested include keloids, hypertrophic scars, scarred tendons, glaucoma, herniated intervertebral discs, and as an adjunct to vitrectomy. The Company is evaluating its options for development of additional indications using collagenase.

SPONSORED STORIES